脱靶药物不良反应的药物基因组学研究
本文综述了脱靶药物不良反应(ADR)的遗传关联及其机制,重点关注具有免疫介导临床表型的反应。许多严重迟发型免疫介导ADR与人类白细胞抗原(HLA)强关联,但仅小部分成功用于筛查;药物代谢等因素也贡献风险。未来药物基因组学靶点将应用于药物设计和临床前测试以改善患者安全。
要点
- 脱靶ADR不可基于已知药理作用预测,部分缺乏免疫记忆。
- 严重迟发型免疫介导ADR与HLA强关联,但筛查实施有限。
- 药物代谢等因素也参与免疫介导ADR风险。
核心结论
- 脱靶药物不良反应的遗传关联研究有助于揭示疾病病理生理、治疗靶点和生物标志物。
- 许多严重迟发型免疫介导ADR与HLA强关联,但仅小部分成功实施筛查。
- 未来药物基因组学靶点将用于药物设计和临床前测试以选择最佳治疗。
研究设计与样本
- 本文为综述,聚焦脱靶药物不良反应的遗传关联及机制。
主要发现
- 脱靶ADR可表现为斑丘疹、严重皮肤不良反应(SCAR)、血管性水肿、瘙痒和支气管痉挛。
- 部分脱靶ADR缺乏免疫记忆,当前数据对疾病病理生理、治疗靶点和生物标志物有信息价值。
- 许多严重迟发型免疫介导ADR显示强HLA关联,但仅小部分成功实施筛查。
- 药物代谢等其他因素已被证明贡献免疫介导ADR风险。
临床怎么用
- 发现特定基因与ADR表型的关联是临床转化为筛查预防的基础。
- 未来药物基因组学靶点及其与药物相互作用的理解将用于药物设计和临床前测试。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Off-target adverse drug reactions (ADRs) are associated with significant morbidity and costs to the healthcare system, and their occurrence is not predictable based on the known pharmacological action of the drug's therapeutic effect. Off-target ADRs may or may not be associated with immunological memory, although they can manifest with a variety of shared clinical features, including maculopapular exanthema, severe cutaneous adverse reactions (SCARs), angioedema, pruritus and bronchospasm. Discovery of specific genes associated with a particular ADR phenotype is a foundational component of clinical translation into screening programmes for their prevention. In this review, genetic associations of off-target drug-induced ADRs that have a clinical phenotype suggestive of an immunologically mediated process and their mechanisms are highlighted. A significant proportion of these reactions lack immunological memory and current data are informative for these ADRs with regard to disease pathophysiology, therapeutic targets and biomarkers which may identify patients at greatest risk. Although many serious delayed immune-mediated (IM)-ADRs show strong human leukocyte antigen associations, only a small subset have successfully been implemented in screening programmes. More recently, other factors, such as drug metabolism, have been shown to contribute to the risk of the IM-ADR. In the future, pharmacogenomic targets and an understanding of how they interact with drugs to cause ADRs will be applied to drug design and preclinical testing, and this will allow selection of optimal therapy to improve patient safety.
引用
- Garon SL, Pavlos RK, White KD, et al. Pharmacogenomics of off-target adverse drug reactions. Br J Clin Pharmacol. 2017. PMID: 28345177. doi:10.1111/bcp.13294
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。